PPARG and metabolic dysfunction-associated steatotic liver disease: However, another study reported that targeted deletion of PPARG inhibited hepatic steatosis in NAFLD mice, while PPARG was highly expressed in NAFLD patients, suggesting its role in promoting steatosis (Yang et al., 2020).